3-(3-苯基-1,2-恶唑-5-基)丙酸 | 61656-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(3-苯基-1,2-恶唑-5-基)丙酸
• 英文名称: 3-(3-Phenylisoxazol-5-yl)propionsaeure
• 英文别名: 3-(3-phenyl-isoxazol-5-yl)-propionic acid；3-(3-Phenyl-1,2-oxazol-5-yl)propanoic acid
• CAS: 61656-43-7
• 化学式: C₁₂H₁₁NO₃
• 分子量: 217.224
• InChiKey: QIBVLSLOHQJUNF-UHFFFAOYSA-N

物化性质

• 沸点：
  420.9±30.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3-苯基-1,2-恶唑-5-基)丙酸 在 pyridinium hydrobromide perbromide 、 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 以61%的产率得到
  参考文献：
  名称：

  氧鎓离子介导的 4-取代螺异恶唑啉合成

  摘要：

  4-溴-螺-异恶唑啉的立体选择性合成是通过对含有侧醇或羧酸官能团的各种异恶唑进行溴化而一步完成的。异恶唑溴化产生溴离子中间体，它通过相邻的氧孤对电子或分子内亲核攻击打开。单个 X 射线晶体数据提供证据表明，螺环异恶唑啉的两个连续立体中心是由亲核试剂相对于溴的反分子内攻击形成的，因为螺环氧和溴原子之间存在反立体化学关系。

  DOI：

  10.1016/j.tetlet.2008.11.053
• 作为产物：
  描述：

  苯甲醛肟 在 N-氯代丁二酰亚胺 、 copper diacetate 、 potassium hydrogencarbonate 、 sodium ascorbate 作用下， 以 水 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 1.0h， 生成 3-(3-苯基-1,2-恶唑-5-基)丙酸
  参考文献：
  名称：

  Larvicidal isoxazoles: Synthesis and their effective susceptibility towards Aedes aegypti larvae

  摘要：

  Twenty 3,5-disubstituted isoxazoles have been synthesized and tested against fourth instar Aedes aegypti larvae. In the synthesis of title compounds, modifications have been made in the C-5 side-chain with a view to test their larvicidal activity. These isoxazoles have been obtained by 1,3-dipolar cycloaddition of arylnitrile oxides to terminal alkynes which furnished the desired products in 20% to 79% yields. A comparative study of the larvicidal activity between 3-(3-aryl-isoxazol-5-yl)-propan-1-ols and 3-(3-aryl-isoxazol-5-yl)-propionic acids clearly demonstrated that the latter compounds possess much better larvicidal activity than the former. We also tested two esters, viz., methyl 3-[3-(phenyl)-isoxazole-5-yl] propionate and methyl 3-[3-(4-chlorophenyl)-isoxazole-5-yl] propionate, where the latter presented an excellent larvicidal profile. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.12.006

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Organic Compounds
  申请人：BHALAY Gurdip

  公开号：US20100130506A1

  公开（公告）日：2010-05-27

  A compound of Formula I in free or salt or solvate form, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  一种以自由形式、盐或溶剂形式存在的I式化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11的含义如规范中所示，可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Synthesis and biological evaluation of fluoro-substituted spiro-isoxazolines as potential anti-viral and anti-cancer agents
  作者：Prasanta Das、Sarah Boone、Dipanwita Mitra、Lindsay Turner、Ritesh Tandon、Drazen Raucher、Ashton T. Hamme

  DOI：10.1039/d0ra06148d

  日期：——

  Electrophilic fluorine-mediated dearomative spirocyclization has been developed to synthesize a range of fluoro-substituted spiro-isoxazoline ethers and lactones. The in vitro biological assays of synthesized compounds were probed for anti-viral activity against human cytomegalovirus (HCMV) and cytotoxicity against glioblastomas (GBM6) and triple negative breast cancer (MDA MB 231). Interestingly,

  亲电氟介导的脱芳香螺环化已被开发用于合成一系列氟取代的螺异恶唑啉醚和内酯。对合成化合物进行体外生物学测定，探讨其对人巨细胞病毒 (HCMV) 的抗病毒活性以及对胶质母细胞瘤 (GBM6) 和三阴性乳腺癌 (MDA MB 231) 的细胞毒性。有趣的是，化合物4d和4n显示出显着的抗HCMV活性（IC 50 ∼ 10 μM），而4l和5f显示出最高的细胞毒性，IC 50 = 36 〜 80 μM。合成功效和生物学相关性为进一步开发氟螺螺异恶唑啉作为新型抗病毒和抗癌药物提供了机会。
• [EN] COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES<br/>[FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DE LA MUCOVISCIDOSE ET D'AUTRES MALADIES CHRONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2011050325A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one compound of Formula I, Formula II, or Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及一种药物组合物，包括一种上皮钠通道活性抑制剂与至少一种公式I、公式II或公式III的化合物结合。本发明还涉及其固体形式和制药配方，以及使用这种组合物治疗CFTR介导疾病，尤其是囊性纤维化的方法。